PROCEPT BioRobotics Corp (NAS:PRCT)

$ 82.01 -1.52 (-1.82%) Market Cap: 4.44 Bil Enterprise Value: 4.40 Bil PE Ratio: 0 PB Ratio: 17.73 GF Score: 54/100

Q3 2024 Procept Biorobotics Corp Earnings Call Transcript
Oct 28, 2024

$91 (+32.33%)

Earnings
Q2 2024 Procept Biorobotics Corp Earnings Call Transcript
Aug 01, 2024

$62 (-2.08%)

Earnings
Q1 2024 Procept Biorobotics Corp Earnings Call Transcript
May 01, 2024

$60.61 (+14.40%)

Earnings
Q4 2023 Procept Biorobotics Corp Earnings Call Transcript
Feb 27, 2024

$50.75 (+3.91%)

Earnings
Q3 2023 PROCEPT BioRobotics Corp Earnings Call Transcript
Nov 01, 2023

$27.55 (+2.84%)

Earnings
Q2 2023 PROCEPT BioRobotics Corp Earnings Call Transcript
Jul 27, 2023

$35.14 (-7.14%)

Earnings
PROCEPT BioRobotics Corp at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 PROCEPT BioRobotics Corp Earnings Call Transcript
Apr 27, 2023

$26.7 (-25.31%)

Earnings
Q4 2022 PROCEPT BioRobotics Corp Earnings Call Transcript
Feb 28, 2023

$37.45 (+0.24%)

Earnings
PROCEPT BioRobotics Corp at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q3 2022 Procept Biorobotics Corp Earnings Call Transcript
Nov 03, 2022

$44 (-0.48%)

Earnings
Q2 2022 Procept Biorobotics Corp Earnings Call Transcript
Aug 04, 2022

$38.37 (-4.77%)

Earnings
Procept Biorobotics Corp At The American Urology Association Annual Meeting Call Transcript
May 13, 2022
Procept Biorobotics Corp at Bank of America Healthcare Conference Transcript
May 11, 2022
Q1 2022 Procept Biorobotics Corp Earnings Call Transcript
May 05, 2022

$35.13 (-5.59%)

Earnings
Q4 2021 Procept Biorobotics Corp Earnings Call Transcript
Mar 08, 2022

$24.99 (+6.20%)

Earnings
Q3 2021 Procept Biorobotics Corp Earnings Call Transcript
Nov 04, 2021

$43.97 (-2.25%)

Earnings

Q1 2022 Procept Biorobotics Corp Earnings Call Transcript

May 05, 2022 / 08:30PM GMT

Release Date Price: $35.13 (-5.59%)

Transcript 10-Q8-K

Matthew James Bacso

Gilmartin Group LLC - Principal

Thanks, operator. Good afternoon, and thank you for participating in today's call. Joining me from PROCEPT BioRobotics are Reza Zadno, CEO; and Kevin Waters, CFO. Earlier today, PROCEPT released financial results for the quarter ended March 31, 2022. A copy of the press release is available on the company's website.

Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.

All forward-looking statements, including, without limitation, those related to our sales and operating trends and future financial performance, expense management expectations for hiring or growth, market opportunity, revenue guidance, commercial expansion, the impact of COVID-19 on

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.